Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocols

Massimo Breccia, Clara Minotti, Roberto Latagliata, Giuseppina Loglisci, Adriano Salaroli, Maria Giovanna Loglisci, Francesco Lo-Coco

Research output: Contribution to journalArticle

Abstract

Despite the impressive results obtained with standard chemotherapy, approximately 20% of acute promyelocytic leukemia (APL) patients undergo disease relapse thereby requiring salvage therapy. Few data is available on long-term prognosis in relation to time to complete remission (CR): we reviewed 142 patients treated with AIDA protocols and we found that 42 out of 142 (29.6%) patients achieved CR after 35 days (median time, 42 days). No significant differences in presenting features, including FAB subtype, type of PML/RARA transcript and relapse risk at presentation between the two patient groups achieving CR > or

Original languageEnglish
Pages (from-to)383-385
Number of pages3
JournalLeukemia Research
Volume37
Issue number4
DOIs
Publication statusPublished - Apr 2013

Keywords

  • APL
  • ATRA
  • Prognosis

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocols'. Together they form a unique fingerprint.

  • Cite this